Related Experiment Videos

[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes]

M Hanefeld1, S Fischer

  • 1Zentrum für Klinische Studien, GWT-TU Dresden mbH.

MMW Fortschritte Der Medizin
|April 2, 2003
PubMed

Insights

Effective type 2 diabetes management requires individualized therapy targeting insulin resistance and impaired insulin secretion. Early combination therapy, especially with metformin for overweight patients, is crucial when monotherapy fails to normalize blood glucose levels.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes treatment involves a broad range of oral agents and insulins.
  • Therapy should address core pathophysiological defects: insulin resistance and impaired early insulin secretion.
  • Fasting and postprandial blood glucose levels are key indicators for assessing these defects.

Purpose of the Study:

  • To outline an individualized, pathophysiologically oriented therapeutic approach for type 2 diabetes.
  • To emphasize the importance of early combination therapy when monotherapy is insufficient.
  • To highlight metformin's role in combination therapy, particularly for overweight patients.

Main Methods:

  • Assessment of therapeutic strategies based on understanding type 2 diabetes pathophysiology.
  • Evaluation of treatment outcomes by monitoring fasting blood glucose, postprandial blood glucose, and HbA1C.
  • Consideration of patient characteristics, such as weight, in treatment selection.

Main Results:

  • Monotherapy often fails to achieve normalization of the glucose triad (fasting blood glucose, postprandial blood glucose, HbA1C).
  • Early application of complementary combination therapies offers significant advantages.
  • Metformin is preferred in combination therapy for overweight patients, including combinations with insulin.

Conclusions:

  • Individualized therapy targeting insulin resistance and impaired insulin secretion is essential for type 2 diabetes.
  • Early combination therapy is recommended when glycemic targets are not met with monotherapy.
  • Metformin-based combinations, including with insulin, are valuable therapeutic options, especially for overweight individuals.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...